|
| Clinical researches on programmed death-1/programmed death ligand-1 immunity checkpoint inhibitors in solid tumor therapy |
| Received:June 25, 2017 Revised:July 31, 2017 |
| View Full Text View/Add Comment Download reader |
| DOI：10.11915/j.issn.1671-5403.2017.12.221 |
| Key words:tumor biomarkers checkpoint inhibitors programmed death-1/programmed death ligand-1 |
|
| Hits: 1898 |
| Download times: 1715 |
| Abstract: |
| In recent years, the inhibitors for immunity checkpoint molecules, programmed death-1/programmed death ligand-1 (PD-1/PD-L1), have obtained encouraging results in solid tumor therapy. PD-1, which is mainly expressed in activated T and B cells, plays a vital role in preventing autoimmune and auto-inflammatory reactivity in the normal host. However, PD-1/PD-L1 expres-sion is very high in the tumor microenvironment, which makes T cell activity be suppressed excessively. So tumor cells can escape immune response. PD-L1 expression level may be a predictive biomarker of its antibody treatment effect. Due to responses of long duration and less toxicity, a minority of patients benefit obviously from immunotherapy. In this article, we illuminated the present resear-ches on PD-1/PD-L1 antibody in treatment of malignant melanoma, lung cancer, urothelial carcinoma, renal cell carcinoma, and so on, and also discussed the biomarkers for patient selection. |
| Close |
|
|
|